Preliminary Schedule of Events

HTRS Research Colloquium: March 8-9
Agenda: Day 1 | Day 2

FWGBD Colloquium: March 9
Agenda

Multidisciplinary Pre-Conference:  March 10-11
Agenda: Day 1 | Day 2

HTRS Scientific Symposium:  March 10-12
Agenda: Day 1 | Day 2 | Day 3

Eastern Time

Event

12:30 PM – 1:00 PM ET

PRE-MEETING NETWORKING “BRING YOUR OWN LUNCH”

1:00 PM ET

OPENING REMARKS

Wolfgang Bergmeier, PhD, and Margaret V. Ragni, MD, MPH, 2021 Colloquium Co-Chairs

1:05 PM – 1:50 PM ET

PLENARY SESSION: “HOW DO I BEGIN, AND WHO IS GOING TO PAY FOR THIS?”

RESEARCH FUNDING TRENDS AND OPPORTUNITIES

Moderator: Margaret V. Ragni, MD, MPH
 

Speaker: Andrei Kindzelski, MD, National Institutes of Health (NIH)

1:50 PM – 2:20 PM ET

NETWORKING BREAK -OR- MENTORING SESSIONS

2:20 PM – 3:20 PM ET

PANEL PRESENTATION: “GETTING A JOB – A RECRUITER’S PERSPECTIVE”

Moderator: Wolfgang Bergmeier, PhD

2:20 PM

BASIC SCIENCE PERSPECTIVE

James Morrissey, PhD, Professor, University of Michigan

2:35 PM

CLINICAL SCIENCE PERSPECTIVE

Janis Abkowitz, PhD, Professor, Hematology Division Head, University of Washington

2:50 PM

TRANSLATIONAL SCIENCE PERSPECTIVE

Jorge Di Paola, MD, Professor/Division Chief, Washington University in St. Louis

3:05 PM

INDUSTRY PERSPECTIVE

Robert Peters, PhD, Sanofi Genzyme

3:20 PM – 4:00 PM ET

ROUNDTABLE DISCUSSIONS

• Basic Science Tables
• Clinical Science Tables
• Translational Science Tables
• Population Science Tables

4:00 PM ET

DAY ONE PROGRAM ENDS

Session resumes Tuesday, March 9 at 12:30 PM ET

Eastern Time

Event

9:30 AM – 9:45 AM ET

CONVENE AND WELCOME

Andra H. James, MD, MPH

9:45 AM – 9:55 AM ET

UTERINE HEMOSTASIS OVERVIEW

9:55 AM – 10:15 AM ET

WOMEN & GIRLS WITH HEMOPHILIA

Sarah H. O’Brien, MD, MSc

10:15 AM – 10:30 AM ET

BREAK

10:30 AM – 11:00 AM ET

MANAGEMENT OF DELIVERY IN WOMEN WITH HEMOPHILIA

Andra H. James, MD, MPH

11:00 AM – 11:30 AM ET

RISK OF CLOTTING ON HORMONAL THERAPY

Naomi Tepper, MD, MPH

11:30 AM – 12:05 PM ET

IS IT HELLP SYNDROME? IS IT TTP? IS IT ATYPICAL HUS? DOES IT MATTER?

Gowthami Arepally, MD

12:05 – 12:30 PM ET

DISCUSSION AND WRAP-UP

Eastern Time

Event

12:30 PM – 1:00 PM ET

PRE-MEETING NETWORKING “BRING YOUR OWN LUNCH”

1:00 PM – 1:05 PM ET

DAY TWO - OPENING REMARKS

Ming Y. Lim, MD/MBBCH, MSCr, and Joshua Muia, PhD, 2021 Colloquium Planning Committee Members

1:05 PM – 1:50 PM ET

PLENARY SESSION: “CRITICAL STEPS FOR A SUCCESSFUL CAREER IN ACADEMIC MEDICINE”

Moderator: Mary Cushman, MD, MSc
 

Speaker: Mark T. Gladwin, MD, Jack D. Myers Distinguished Professor and Chair, Chairman of the Department of Medicine, UPMC and the University of Pittsburgh School of Medicine

1:50 PM – 2:10 PM ET

BREAKOUT SESSION 1: “PRACTICAL TOOLS EVERYONE NEEDS TO ADVANCE THEIR CAREERS”

BREAKOUT 1

SPEAK UP:  GIVING EFFECTIVE PRESENTATIONS

Discussion Leader: Alisa S. Wolberg, PhD

BREAKOUT 2

MANAGING THE K-TO-R TRANSITION:  WHAT TO DO IF YOU DON’T GET A K-AWARD

Discussion Leader: Nigel Key, MB, ChB, FRCP

BREAKOUT 3

FROM GOOD IDEA TO SUBMITTED GRANT

Discussion Leader: Gowthami Arepally, MD

BREAKOUT 4

BEGIN AGAIN:  JUMP START YOUR RESEARCH CAREER AFTER A BREAK

Discussion Leader: Menaka Pai, BSc, MSc, MD, FRCPC

2:10 PM – 2:30 PM ET

“GET UP AND STRETCH BREAK’ -OR- MENTORING SESSIONS

2:30 PM – 2:50 PM ET

BREAKOUT SESSION 2: “PRACTICAL TOOLS EVERYONE NEEDS TO ADVANCE THEIR CAREERS”

BREAKOUT 1

SPEAK UP:  GIVING EFFECTIVE PRESENTATIONS

Discussion Leader: Alisa S. Wolberg, PhD

BREAKOUT 2

MANAGING THE K-TO-R TRANSITION:  WHAT TO DO IF YOU DON’T GET A K-AWARD

Discussion Leader: Nigel Key, MB, ChB, FRCP

BREAKOUT 3

FROM GOOD IDEA TO SUBMITTED GRANT

Discussion Leader: Gowthami Arepally, MD

BREAKOUT 4

BEGIN AGAIN:  JUMP START YOUR RESEARCH CAREER AFTER A BREAK

Discussion Leader: Menaka Pai, BSc, MSc, MD, FRCPC

2:50 PM – 3:35 PM ET

PANEL PRESENTATION: “OVERCOMING OBSTACLES: MOVING YOUR CAREER FORWARD”

Moderator:  Rodney Camire, PhD

2:50 PM

BASIC/TRANSLATIONAL SCIENCE PERSPECTIVE

Veronica H. Flood, MD

3:05 PM

CLINICAL SCIENCE PERSPECTIVE

Margaret V. Ragni, MD, MPH

3:20 PM

INDUSTRY PERSPECTIVE

Marcus Carr, MD

3:35 PM – 4:20 PM ET

CLOSING RECEPTION “BRNG YOUR OWN SNACKS

4:20 PM ET

DAY TWO PROGRAM ENDS

                               Eastern Time                    

Event

10:00 AM – 10:05 AM ET

DAY ONE - OPENING REMARKS

Loren D’Angelo, RN-BC, BSN, MSN, CPNP-PC, HTRS 2021 Planning Committee

10:05 AM – 11:30 AM ET

PRE-CONFERENCE SESSION 1: “NEW THERAPIES”

Moderators: Loren D’Angelo, RN-BC, BSN, MSN, CPNP-PC, and Caitlin Moncrieff, NP

10:05 AM

DOACS IN THE PEDIATRIC POPULATION

Riten Kumar, MD, MSc

10:35 AM

MANAGING INHIBITORS IN THE REALM OF NON-FACTOR THERAPIES

James Munn, RN-BC, BS, BSN, MS

10:55 AM

“GENE THERAPY CLINICAL TRIAL EXPERIENCES IN CARE”

Darcy Phelan, NP, MSN

11:20AM

Live Q&A

11:30 AM

DAY ONE PROGRAMMING ENDS

Session resumes Thursday, March 11 at 10:00 AM ET

Eastern Time

Event

12:00 PM – 1:00 PM ET

SATELLITE SYMPOSIA: (2) Concurrent Sessions

Sanofi Genzyme: "siRNA Technology in Hemophilia" Presenters: Guy Young, MD

CSL Behring: "On-Demand Bleed Resolution in Hemophilia B With an Extended Half-Life Factor IX Therapy" Presenter: Miguel Escobar, MD

1:00 PM – 1:05 PM ET

OPENING REMARKS

Jordan Shavit, MD, PhD, HTRS 2021 Planning Committee Chair

Ayesha N. Zia, MD, HTRS 2021 Planning Committee Vice Chair

1:05 PM – 2:30 PM ET

1:05 PM – 1:10 PM

1:10 PM – 1:20 PM

1:20 PM – 1:25 PM

1:25 PM – 1:40 PM

1:40 PM – 1:55 PM

1:55 PM – 2:05 PM

2:05 PM – 2:15 PM

2:15 PM – 2:25 PM

2:25 PM – 2:30 PM

SYMPOSIUM SESSION 1 DEBATE: “THE FUTURE OF HEMOPHILIA THERAPEUTICS:  SUBSTITUTION OR GENE THERAPY?”

Moderators: Jordan Shavit, MD, PhD and Yasmina Abajas, MD

Speakers: Denise E. Sabatino, PhD, Michael Callaghan, MD, and Shawn Jobe, MD, PhD

Case Presentation & Introduction to Audience Response System (“ARS”)

Jordan Shavit, MD, PhD and Yasmina Abajas, MD

Introduction: “The science behind hemophilia therapeutics”

Denise E. Sabatino, PhD

Pre-Debate ARS Vote

Jordan Shavit, MD, PhD and Yasmina Abajas, MD

Argument for Substitution

Michael Callaghan, MD

Argument for Gene Therapy

Shawn Jobe, MD, PhD

Rebuttal for Substitution

Michael Callaghan, MD

Rebuttal for Gene Therapy

Shawn Jobe, MD, PhD

Questions/Discussion

Jordan Shavit, MD, PhD and Yasmina Abajas, MD

Post-Debate ARS Vote

Jordan Shavit, MD, PhD and Yasmina Abajas, MD

2:30 PM – 3:30 PM ET

NETWORKING & EXHIBITOR SPEED BREAK

3:30 PM – 4:30 PM ET

ORAL ABSTRACT PRESENTATIONS: (2) Concurrent Sessions

vWF/HEMOPHILIA A
Moderators: Christine Kempton, MD, MSc
and Joshua Muia, PhD

Novel Mechanisms & Trials
Moderators: A. Valance Washington, PhD
and Lauren Amos, MD

3:30 PM

“THE IMPORTANCE OF GENETIC TESTING IN DIAGNOSING VON WILLEBRAND'S DISEASE TYPE 2M”
Presenter: Radia Ksayer, MD

“PLATELETS FACTOR 4 (PF4) BINDING ENHANCES IN VITRO NEUTROPHIL EXTRACELLULAR TRAPS (NET) CAPTURE OF SARS-COV-2: THERAPEUTIC IMPLICATIONS”
Presenter: Maki Ishizuka, MD

3:45 PM

“VON WILLEBRAND FACTOR (VWF) MULTIPLEX ACTIVITY ASSAY DIFFERENTIATION OF LOW VWF/TYPE 1 VON WILLEBRAND DISEASE (VWD) AND VARIANT VWD: ANALYSIS FROM THE COMPARATIVE EFFECTIVENESS IN THE DIAGNOSIS OF VWD” Presenter: Jonathan C. Roberts, MD

“IN VITRO-GROWN MEGAKARYOCYTES (MKS) TAKE UP THE ECTOPIC PROTEIN UROKINASE (UPA) AND THE RESULTING PLATELETS (PLTS) CAN RELEASE THE UPA AT SITES OF VASCULAR INJURY” Presenter: Sergei V. Zaitsev, PhD

4:00 PM

Non-CME Presentation: “BROAD PATIENT ELIGIBILITY AND LONG-TERM TOLERABILITY IN THE FIRST-IN-HUMAN GENE THERAPY STUDY OF AAVHU37.HFVIIICO IN SEVERE HEMOPHILIA A” Presenter: Francesca Ferrante, MD

“BLEEDING DIATHESIS IN MICE LACKING JAK2 IN PLATELETS”
Presenters: Nathan Eaton, BSc

4:15 PM

Non-CME Presentation: “REAL-WORLD DATA FROM A US CLAIMS DATABASE AMONG PATIENTS WITH HEMOPHILIA A TREATED WITH RECOMBINANT FVIII FC FUSION PROTEIN” Presenter: Amanda Wilson, MPH, PhD

“A RANDOMIZED, PRAGMATIC TRIAL TO ASSESS A PEDIATRIC REAL-TIME RISK PREDICTION MODEL FOR THROMBOTIC EVENTS” Presenters: Shannon C. Walker, MD

4:30 PM - 5:30 PM ET

OPEN NETWORKING

5:30 PM - 6:30 PM ET

SATELLITE SYMPOSIA: (2) Concurrent Sessions

Takeda: Presenter: Tammuella Chrisentery Singleton, MD 

6:30 PM ET

DAY ONE PROGRAMMING ENDSe

General Session resumes Thursday, March 11 at 12:00 PM ET

Eastern Time

Event

10:00 AM – 10:05 AM ET

DAY TWO - OPENING REMARKS

Loren D’Angelo, RN-BC, BSN, MSN, CPNP-PC, HTRS 2021 Planning Committee

10:05 AM – 11:30 AM ET

PRE-CONFERENCE SESSION 2: INCLUSIVE CARE

Moderators: Mary Lesh, PNP, MSN and Caitlin Moncrieff, NP

10:05 AM

TRAUMA INFORMED CARE FOR HEMATOLOGY PROVIDERS

Amanda Stahl, LICSW

10:35 AM

HEMATOLOGIC CONSIDERATIONS IN THE CARE OF TRANSGENDER PATIENTS

Meredith Russel, PNP, MSN

11:15 AM

Live Q&A

11:30 AM ET

HTRS 2021 Multidisciplinary Pre-conference Ends

Eastern Time

Event

12:00 PM – 1:00 PM ET

SATELLITE SYMPOSIA: (2) CONCURRENT SESSIONS

Novo Nordisk: "A rFVIIa with over 30 years of experience with treating hemophilia and other rare bleeding disorders" Presenters: Stephanie Seremetis, MD, Miguel Escobar, MD, and Joanna Davis, MD

Bayer: "Patient focused prophylaxis management for patients with hemophilia: a case-based discussion” Presenter: Stacy Croteau, MD, MMS

1:00 PM – 1:05 PM ET

OPENING REMARKS

Jordan Shavit, MD, PhD, HTRS 2021 Planning Committee Chair

Ayesha N. Zia, MD, HTRS 2021 Planning Committee Vice Chair

1:05 PM – 2:10 PM ET

SYMPOSIUM SCIENTIFIC SESSION 2: STATE-OF-THE-ART LECTURE: “COVID-19: THROMBOSIS AND CLINICAL CONSIDERATIONS”

Moderator: Jordan A. Shavit, MD, PhD and Andrea Obi, MD, Co-moderator

Speakers: Roger Lewis, MD, Robert Campbell, PhD, and Hanny Al-Samkari, MD

2:10 PM - 3:10 PM ET

EXCLUSIVE SATELLITE SYMPOSIUM
GENENTECH: "SubQ Prophylaxis for Hemophilia A: 3 Experts Discuss the Latest Data From the Pivotal Trials"
Presenters: Amy Shapiro, MD,  Michael Callaghan, MD, and Guy Young, MD

3:10 PM – 4:10 PM ET

ORAL ABSTRACT PRESENTATIONS: (2) Concurrent Sessions

THROMBOSIS
Moderators: Hervé Falet, PhD

and Rachel Rosovsky, MD

HEMOPHILIA B
Moderators: Lacramioara Ivanciu, PhD

and Janice Staber, MD

3:10 PM

“INVESTIGATING THE REGULATION OF RAP1-INTEGRIN SIGNALING PATHWAY USING THE IMMKCL MEGAKARYOCYTE MODEL” Presenter: Ankita Dhenge, PhD

“AMT-060 GENE THERAPY IN ADULTS WITH SEVERE OR MODERATE-SEVERE HEMOPHILIA B CONFIRM STABLE FIX EXPRESSION AND SUSTAINED REDUCTIONS IN BLEEDING AND FACTOR IX USE FOR UP TO 5 YEARS”
Presenter:  Frank W.G Leebeek, MD, PhD

3:25 PM

“FORMATION OF PROTHROMBINASE ON HUMAN ENDOTHELIAL CELLS” Presenter: Clay T. Cohen, MD

“ETRANACOGENE DEZAPARVOVEC (AAV5-PADUA HFIX VARIANT), AN ENHANCED VECTOR FOR GENE TRANSFER IN ADULTS WITH SEVERE OR MODERATE-SEVERE HEMOPHILIA B: TWO YEAR DATA FROM A PHASE 2B TRIAL”
Presenter: Annette von Drygalski, MD, PharmD

3:40 PM

“HEMATOLOGIC ABNORMALITIES AND VENOUS THROMBOPROPHYLAXIS IN MIS-C:  DATA FROM A MULTI-DISCIPLINARY WORKING GROUP AT A PEDIATRIC TERTIARY CARE HOSPITAL” Presenter: Lynn M. Malec, MD, MSc

“EFFICACY AND SAFETY OF ETRANACOGENE DEZAPARVOVEC IN ADULTS WITH SEVERE OR MODERATE-SEVERE HEMOPHILIA B: FIRST DATA FROM THE PHASE 3 HOPE-B GENE THERAPY TRIAL”
Presenter:  Steven W. Pipe, MD

3:55 PM

“RISK OF VENOUS THROMBOEMBOLISM IN PEDIATRIC HOSPITALIZED PATIENTS UNDERGOING NON-CARDIAC SURGERY, A REPORT FROM THE CHILDREN'S HOSPITAL-ACQUIRED THROMBOSIS (CHAT) CONSORTIUM”
Presenter: Elizabeth T. Stephens, DO

Non-CME Presentation: “CLEARANCE OF FIDANACOGENE ELAPARVOVEC VECTOR DNA IN PATIENTS WITH SEVERE OR MODERATELY SEVERE HEMOPHILIA B (HB)”

Presenter:  Patrick F. Fogarty, M

4:10 PM – 4:15 PM ET

TRANSITION TO REMO

4:15 PM – 5:15 PM ET

POSTER PRESENTATIONS + SPEED SESSIONS

• “A Survey of Anti-platelet and Anticoagulant Use in Persons with Hemophilia” Presenter: Maissaa Janbain, MD, MSCR
• “Bleeding Disorder Referrals to Hematology Clinic: A Single Institution Experience” Presenter: Zuri Hudson, DO
• “Catastrophic Thrombotic Syndrome in Systemic Lupus Erythematosus without Antiphospholipid Antibodies” Presenter: Krystal J. Park, MD
• “Drive-through Anticoagulation Clinic During COVID-19 Pandemic” Presenter: Vilmarie Rodriguez, MD
• “ECMO Blood Product Utilization: The First 24 Hours” Presenter: Anusha Chidharla, MD
• “Eculizumab Treatment for Refractory Thrombosis in Antiphospholipid Syndrome” Presenter: Habiba Hussain, MD
• “Efficacy and Safety of Damoctocog Alfa Pegol is Sustained for up to ≥6 Years of Observation in Patients Aged 12– Presenter: Jonathan Ducore, MD, MPH
• “Gastrointestinal Bleeding in Patients with von Willebrand Disease: Treatments and Outcomes” Presenter: Jonathan C. Roberts, MD
• “Implementation and Analysis of a Venous Thromboembolism Prophylaxis Algorithm in Hospitalized Pediatric Patients”
  Presenter: Nora M. Gibson, MD
• “NHF Builds a Community-Driven National Research Agenda for Inherited Bleeding Disorders” Presenter: Michelle L. Witkop, DNP, FNP-BC
• “Perceptions about the use and efficacy of Extended Half-Life (EHL) factor products in persons with hemophilia: A national survey of providers from Hemophilia Treatment Centers in the United States” Presenter: Neeraja Swaminathan, MBBS
• “Single Center Experience of Bleeding Evaluation in Hemophilia Carriers using ISTH-BAT” Presenter: Maria Carter Febres, MD
• “Successful Implementation of a Pediatric Bleeding Assessment Tool in the Electronic Medical Record in an Academic Clinical Setting” Presenter: Kelly Bajorek, BS
• “Surgical Procedures in Patients with Hemophilia: Multistakeholder Perspectives From 2018 Roundtables” Presenter: Miguel A. Escobar, MD
• “Telegenetic Counseling for Female My Life, Our Future Participants” Presenter: Maria E. Santaella, RN-BC, MSN, CPHON
• “Thromboprophylaxis to Improve Outcomes in COVID-19: An Indian Expert Consensus” Presenter: Agam Vora, MD
• “Unprovoked extensive deep vein thrombosis in a pediatric patient with sickle cell disease and duplicated inferior vena cava”
  Presenter: Ramya Ramakrishnan, MD
• “Venous Thromboembolic Disease in Children Associated with COVID-19” Presenter: Shalu Narang, MD MPH
• Non-CME Presentation: “Single-dose Pharmacokinetics, Efficacy, and Safety of Fibrinogen Concentrate for On-Demand Treatment of Acute Bleeding and Surgical Prophylaxis in Patients with Congenital Fibrinogen Deficiency” Presenter: Bruce Schwartz, PhD

5:15 PM – 6:15 PM ET

OPEN NETWORKING

6:15 PM – 7:15 PM ET

SATELLITE SYMPOSIA: 2 Concurrent Sessions

Takeda (CME) | Novo Nordisk

7:15 PM

DAY TWO PROGRAMMING ENDS

General Session resumes Friday, March 12 at 12:00 PM ET

Eastern Time

Event

12:00 PM – 1:00 PM ET

SATELLITE SYMPOSIA: (2) Concurrent Sessions

Sanofi Genzyme: "A Breakthrough in aTTP Treatment: Now recommended by the ISTH Guidelines" Presenters: Jay Raval, MD

Alnylam Pharmaceuticals

1:00 PM – 1:05 PM ET

OPENING REMARKS

Jordan Shavit, MD, PhD, HTRS 2021 Planning Committee Chair

Ayesha N. Zia, MD, HTRS 2021 Planning Committee Vice Chair

1:05 PM – 2:10 PM ET

SCIENTIFIC SESSION 3: “BENCH, CLINIC, AND EVERYTHING IN-BETWEEN” (3) Concurrent Sessions

Session 3-A: “Platelets”
Moderators: Pavel Davizon-Castillo, MD and Jorge Di Paola, MD, Co-moderator

Speakers: Rachael Grace, MD, Jeanne Hendrickson, MD, Kellie Machlus, PhD

Session 3-B: “Sickle Cell-Associated Thrombosis”
Moderators: Courtney Thornburg, MD and Deirdre S. Nolfi-Donegan, MD, Co-moderator

Speakers: Morey Blinder, MD, Erica Sparkenbaugh, PhD, Huanghe Yang, PhD

Session 3-C: “Post-VTE Functional Syndromes”

Moderators: Ayesha N. Zia, MD and Marisol Betensky, MD, MPH, Co-moderator

Speakers: Susan Kahn, MD, MSc, FRCPC, ABIM, Farouc Jaffer, MD, PhD, Peter Henke, MD

2:10 PM – 2:20 PM ET

TRANSITION TO REMO

2:20 PM – 3:20 PM ET

NETWORKING & EXHIBITOR SPEED BREAK

3:20 PM – 4:20 PM ET

POSTER PRESENTATIONS AND SPEED SESSIONS

• “ATHN 16: Safety of Coagulation Factor VIIa (recombinant)-jncw for the Treatment of Bleeding Events in Patients with Hemophilia A or B with Inhibitors with or without Prophylactic Treatment” Presenter: Michael Callaghan
• “Clinical Study to Investigate the Efficacy and Safety of a Von Willebrand Factor FVIII Concentrate (VWF/FVIII) during Prophylaxis in Previously Treated Patients with Von Willebrand Disease (VWD)” Presenter: Robert               Sidonio
• “Community Voices in Research (CVR); A Patient-Centric Approach Moving the Future of Inherited Bleeding Disorders Forward” Presenter: Rosaura Vidal
• "Development & Testing of an Asynchronous Hemophilia Learning Module” Presenter: Tiffany Lucas
• “Evaluation of the hemostatic efficacy of eptacog beta (recombinant factor VIIa) for the treatment of bleeding in pediatric subjects ( Presenter: Steven Pipe
• “Examination and Validation of a Patient-Centric Joint Metric: “PROBLEM JOINT”; Empirical Evidence from the CHESS US Dataset” Presenter: Tom Burke
• “How to Reduce Hypercoagulability Testing in the Inpatient Setting? A Quality Improvement Initiative” Presenter: James Hall
• HTRS Student Research Award: “Development of an immunoproteomic pipeline for the characterization of anti-FVIII
• molecular and cellular repertoires in hemophilia A inhibitor patients” Presenter: Robert Chen
• HTRS Student Research Award: “Risk Factors for Non-Variceal Hemorrhage in Patients with Chronic Liver Disease“ Presenter: Preethi Kesavan
• “Magnetically powered microwheel thrombolysis of occlusive thrombi in zebrafish” Presenter: Jordan Shavit
• “Management of Recurrent Disease in Acquired Hemophilia A” Presenter: Aaron Boothby
• “Passive Infusion Logging System (PILS): A pilot” Presenter: Maria Santaella

• HTRS Student Research Award: “Reduced Health-Related Quality of Life is Associated with Depression and Cognitive Impairment Among Survivors of Thrombotic Thrombocytopenic Purpura” Presenter: Sruthi Selvakumar
• “SHORT-TERM OUTCOME of NEONATAL VENOUS THROMBOEMBOLISM for ANTICOAGULATED and OBSERVED PATIENTS”
  Presenter: Kisha Beg
• “The Safety of Eptacog Beta in Hemophilia Patients with Inhibitors in Adult, Pediatric, and Surgical Settings”
  Presenter: Miguel Escobar
• “The value of immature platelet fraction of platelet apheresis products in prediction of platelet transfusion response in thrombocytopenic cancer patients” Presenter: Ekrem Turk
• “Warfarin-induced skin necrosis in patients with protein C and S hereditary deficiency. Systematic review”
  Presenter: Rafael Pichardo-Rodriquez
• Non-CME Presentation: “Eighteen-Month Interim Analysis of Efficacy and Safety of Givosiran, an RNAi Therapeutic for Acute Hepatic Porphyria, in the ENVISION Open Label Extension” Presenter: David Rees
• Non-CME Presentation:  Clinical Outcomes in Patients with Acute Hepatic Porphyria Treated with Givosiran Who Stopped Hemin Prophylaxis at Study Entry: A Post-hoc Analysis from the Phase 3 ENVISION Study Through Month 12”
  Presenter: Herbert Bonkovsky

4:20 PM - 4:30 PM ET

INTRODUCTION TO CLOSING EXTRAVAGANZA

4:30 PM - 5:30 PM ET

CLOSING EXTRAVAGANZA

NETWORKING & THE FIRST-EVER “HTRS TALENT SHOW”

5:30 PM ET

HTRS 2021 SCIENTIFIC SYMPOSIUM PROGRAMMING ENDS

Mark your calendars for the next HTRS Scientific Symposium:

March 10 - 12, 2023

Renaissance Orlando at SeaWorld

Orlando, FL